The Experts below are selected from a list of 114 Experts worldwide ranked by ideXlab platform
Jeffrey L. Ecker - One of the best experts on this subject based on the ideXlab platform.
-
First-trimester sex hormone binding Globulin and subsequent gestational diabetes mellitus
American Journal of Obstetrics and Gynecology, 2003Co-Authors: Ravi Thadhani, Karen Hsu-blatman, Laura Sandler, David Nathan, Myles Wolf, Jeffrey L. EckerAbstract:OBJECTIVE: We sought to examine the association between early pregnancy levels of sex hormone binding Globulin and subsequent gestational diabetes mellitus, an association that has not been studied previously. STUDY DESIGN: We conducted a nested case-control study of 44 patients with gestational diabetes mellitus and 94 women with negative third-trimester screening for gestational diabetes mellitus. Sex hormone binding Globulin levels were measured from serum samples that had been collected in the first trimester, and clinical data were ascertained from prospectively collected electronic medical records. RESULTS: Compared with women without gestational diabetes mellitus, first-trimester sex hormone binding Globulin levels were lower among women in whom gestational diabetes mellitus subsequently developed (187 ± 82 nmol/L vs 233 ± 92 nmol/L, P < .01). In logistic regression analysis that was adjusted for body mass index, age, race, smoking, blood pressure, serum testosterone and estradiol levels, and gestational age at serum collection, sex hormone binding Globulin levels remained independently associated with subsequent gestational diabetes mellitus. For every 50-nmol/L increase in sex hormone binding Globulin, the odds of gestational diabetes mellitus fell by 31% (odds ratio, 0.69; 95% Cl: 0.48, 0.99). CONCLUSION: Sex hormone binding Globulin offers a potential early marker to target women who are at risk for gestational diabetes mellitus.
Marjon N. Mobasseri - One of the best experts on this subject based on the ideXlab platform.
-
Sex Hormone–Binding Globulin Levels as a Predictor for Developing Gestational Diabetes Mellitus
Obstetrics & Gynecology, 2014Co-Authors: Hanh N. Cottrell, Joseph V. Karnitis, Marjon N. MobasseriAbstract:INTRODUCTION: The aim of the this study was to evaluate the association between early pregnancy levels of serum sex hormone-binding Globulin in the first trimester and the development of gestational diabetes mellitus (GDM). Currently, no effective markers in early pregnancy have been established to identify women at risk for GDM. METHODS: Prospective cross-sectional study of 262 pregnant women with sex hormone-binding Globulin levels (mmol/L) that were obtained from initial first trimester prenatal blood panel. Sex hormone-binding Globulin results were compared with current glucola testing (50-g, 1-hour oral glucose challenge test at 24-28 weeks of gestation) in patients with and without the diagnosis of GDM. No interventions were planned on basis of sex hormone-binding Globulin. Clinical delivery records, glucose levels, and complications were collected. RESULTS: Sex hormone-binding Globulin levels compared with screening glucola showed a statistically significant inverse relationship, lower sex hormone-binding Globulin levels correlating with higher glucola values (P
Ravi Thadhani - One of the best experts on this subject based on the ideXlab platform.
-
First-trimester sex hormone binding Globulin and subsequent gestational diabetes mellitus
American Journal of Obstetrics and Gynecology, 2003Co-Authors: Ravi Thadhani, Karen Hsu-blatman, Laura Sandler, David Nathan, Myles Wolf, Jeffrey L. EckerAbstract:OBJECTIVE: We sought to examine the association between early pregnancy levels of sex hormone binding Globulin and subsequent gestational diabetes mellitus, an association that has not been studied previously. STUDY DESIGN: We conducted a nested case-control study of 44 patients with gestational diabetes mellitus and 94 women with negative third-trimester screening for gestational diabetes mellitus. Sex hormone binding Globulin levels were measured from serum samples that had been collected in the first trimester, and clinical data were ascertained from prospectively collected electronic medical records. RESULTS: Compared with women without gestational diabetes mellitus, first-trimester sex hormone binding Globulin levels were lower among women in whom gestational diabetes mellitus subsequently developed (187 ± 82 nmol/L vs 233 ± 92 nmol/L, P < .01). In logistic regression analysis that was adjusted for body mass index, age, race, smoking, blood pressure, serum testosterone and estradiol levels, and gestational age at serum collection, sex hormone binding Globulin levels remained independently associated with subsequent gestational diabetes mellitus. For every 50-nmol/L increase in sex hormone binding Globulin, the odds of gestational diabetes mellitus fell by 31% (odds ratio, 0.69; 95% Cl: 0.48, 0.99). CONCLUSION: Sex hormone binding Globulin offers a potential early marker to target women who are at risk for gestational diabetes mellitus.
Hanh N. Cottrell - One of the best experts on this subject based on the ideXlab platform.
-
Sex Hormone–Binding Globulin Levels as a Predictor for Developing Gestational Diabetes Mellitus
Obstetrics & Gynecology, 2014Co-Authors: Hanh N. Cottrell, Joseph V. Karnitis, Marjon N. MobasseriAbstract:INTRODUCTION: The aim of the this study was to evaluate the association between early pregnancy levels of serum sex hormone-binding Globulin in the first trimester and the development of gestational diabetes mellitus (GDM). Currently, no effective markers in early pregnancy have been established to identify women at risk for GDM. METHODS: Prospective cross-sectional study of 262 pregnant women with sex hormone-binding Globulin levels (mmol/L) that were obtained from initial first trimester prenatal blood panel. Sex hormone-binding Globulin results were compared with current glucola testing (50-g, 1-hour oral glucose challenge test at 24-28 weeks of gestation) in patients with and without the diagnosis of GDM. No interventions were planned on basis of sex hormone-binding Globulin. Clinical delivery records, glucose levels, and complications were collected. RESULTS: Sex hormone-binding Globulin levels compared with screening glucola showed a statistically significant inverse relationship, lower sex hormone-binding Globulin levels correlating with higher glucola values (P
Myles Wolf - One of the best experts on this subject based on the ideXlab platform.
-
First-trimester sex hormone binding Globulin and subsequent gestational diabetes mellitus
American Journal of Obstetrics and Gynecology, 2003Co-Authors: Ravi Thadhani, Karen Hsu-blatman, Laura Sandler, David Nathan, Myles Wolf, Jeffrey L. EckerAbstract:OBJECTIVE: We sought to examine the association between early pregnancy levels of sex hormone binding Globulin and subsequent gestational diabetes mellitus, an association that has not been studied previously. STUDY DESIGN: We conducted a nested case-control study of 44 patients with gestational diabetes mellitus and 94 women with negative third-trimester screening for gestational diabetes mellitus. Sex hormone binding Globulin levels were measured from serum samples that had been collected in the first trimester, and clinical data were ascertained from prospectively collected electronic medical records. RESULTS: Compared with women without gestational diabetes mellitus, first-trimester sex hormone binding Globulin levels were lower among women in whom gestational diabetes mellitus subsequently developed (187 ± 82 nmol/L vs 233 ± 92 nmol/L, P < .01). In logistic regression analysis that was adjusted for body mass index, age, race, smoking, blood pressure, serum testosterone and estradiol levels, and gestational age at serum collection, sex hormone binding Globulin levels remained independently associated with subsequent gestational diabetes mellitus. For every 50-nmol/L increase in sex hormone binding Globulin, the odds of gestational diabetes mellitus fell by 31% (odds ratio, 0.69; 95% Cl: 0.48, 0.99). CONCLUSION: Sex hormone binding Globulin offers a potential early marker to target women who are at risk for gestational diabetes mellitus.
